An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression

BACKGROUND: Many patients with Parkinson’s disease (PD) experience depression. OBJECTIVE: Evaluate pimavanserin treatment for depression in patients with PD. METHODS: Pimavanserin was administered as monotherapy or adjunctive therapy to a selective serotonin reuptake inhibitor or serotonin/noradrena...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Parkinsons Dis
Autori principali: DeKarske, Daryl, Alva, Gustavo, Aldred, Jason L., Coate, Bruce, Cantillon, Marc, Jacobi, Lori, Nunez, Rene, Norton, James C., Abler, Victor
Natura: Artigo
Lingua:Inglês
Pubblicazione: IOS Press 2020
Soggetti:
Research Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7683094/
https://ncbi.nlm.nih.gov/pubmed/32804101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-202058
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi